SUMO1 (タンパク質 | 抗体 | cDNA クローン | ELISA キット)

All SUMO1 reagents are produced in house and quality controlled, including 3 SUMO1 Antibody, 60 SUMO1 Gene, 1 SUMO1 IP Kit, 1 SUMO1 Protein, 2 SUMO1 qPCR. All SUMO1 reagents are ready to use.

SUMO1 Protein (1)

SUMO1 Antibody (3)

SUMO1 cDNA Clone (60)

NM_003352.4

クローニングベクター cDNA 製品

In lentiviral vector

NM_009460.2

クローニングベクター cDNA 製品

In lentiviral vector

NM_001009672.1

クローニングベクター cDNA 製品

In lentiviral vector

NM_001284821.1

クローニングベクター cDNA 製品

In lentiviral vector

SUMO1 の背景知識

Small ubiquitin-like modifier protein (SUMO) modification is a highly dynamic process, catalyzed by SUMO-specific activating (E1), conjugating (E2) and ligating (E3) enzymes, and reversed by a family of SUMO-specific proteases (SENPs). Small ubiquitin-like modifier 1 (SUMO1) is a member of the superfamily of ubiquitin-like proteins. Despite its structural similarity with ubiquitin, SUMO1 does not seem to play any role in protein degradation. SUMO1 plays an important role in modulation of NOX activity required for ROS generation. SUMO1 haploinsufficiency results in cleft lip and palate in animal models. SUMO1 gene variation in human non-syndromic cleft lip with or without cleft palate (NSCLP) development. SUMO-1 may be useful as a novel target for therapy in oral squamous cell carcinoma (SCC) as well as a clinical indicator for tumor recurrence together with Mdm2.

SUMO1 の参考文献

  • Kim HJ, et al. (2011) SUMO1 attenuates stress-induced ROS generation by inhibiting NADPH oxidase 2. Biochem Biophys Res Commun. 410(3): 555-62.
  • Zuo Y, et al. (2009) Small ubiquitin-like modifier protein-specific protease 1 and prostate cancer. Asian J Androl. 11(1): 36-8.
  • Song T, et al. (2008) SUMO1 polymorphisms are associated with non-syndromic cleft lip with or without cleft palate. Biochem Biophys Res Commun. 377(4): 1265-8.
  • Katayama A, et al. (2007) Overexpression of small ubiquitin-related modifier-1 and sumoylated Mdm2 in oral squamous cell carcinoma: possible involvement in tumor proliferation and prognosis. Int J Oncol. 31(3): 517-24.